Small Pharma Analyst
Growth, long/short equity, biotech, healthcare

PTC Therapeutics: A Speculative Buy On Rare Disease Portfolio And Potential Takeover Target

PTC Therapeutics (NASDAQ:PTCT) has a mission to "leverage our knowledge of RNA biology to bring novel therapeutics to patients affected by rare and neglected disorders." The science at PTC is focused on discovering drugs that address so-called "nonsense" genetic mutations and specifically "premature termination codon mutations." These are defects in the DNA sequence in which an amino acid code on a gene is substituted by a stop codon, which halts the sequence and prevents production of a fully functioning protein. PTC mutations are the underlying cause for 10% of all human genetic disease. About 1800 inherited human diseases are caused by nonsense mutations; no treatments are currently available so the unmet medical need is huge.

The PTCT pipeline...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details